LEGN / EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy

Legend Biotech's Carvykti has shown improved uptake in the second quarter. The company aims to reach an annualized capacity of 10,000 doses of Carvykt more_horizontal

Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Shares of Legend Biotech Corp. LEGN, -1.00% gained 3.7% premarket on Thursday after the company said its multiple myeloma therapy Carvykti, a collabor more_horizontal

Legend (LEGN) announces regulatory submission for expanded use of Carvykti to include adult patients with relapsed and lenalidomide-refractory multipl more_horizontal

If everyone expects a stock to rise and buys it, eventually someone will be wrong. Legend Biotech's shares are up by quite a bit this year already. more_horizontal

Legend Biotech Corporation (NASDAQ: LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-b more_horizontal

Legend reportedly confirmed the leaked results of its multiple myeloma study on Friday, leading LEGN stock to surge. The post Legend Bio Hits Profit-T more_horizontal

Leaked data from Legend Biotech's (LEGN) phase III study of the blood cancer drug, Carvykti, shows a 74% reduction in risk of death or tumor progressi more_horizontal